Resistance is reality: findings from the first Ukrainian cumulative antibiogram.


Journal

JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 10 07 2024
accepted: 24 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Antimicrobial resistance is a global health threat resulting in significant morbidity and mortality worldwide. Until recently, in Ukraine, cumulative antibiograms (CuAbgms) have never been available. To describe the first CuAbgm developed in Ukraine. We developed a CuAbgm for the Okhmatdyt National Specialized Children's Hospital using data from WHONET. Antimicrobial susceptibility testing was performed per EUCAST guidelines. The CuAbgm was developed using guidance from CLSI. For In this first-ever CuAbgm developed in Ukraine, high levels of resistance were demonstrated among Gram-negative bacteria. CuAbgms should be prioritized in laboratories in Ukraine to guide empirical antimicrobial therapy, infection control and antimicrobial stewardship policies. This is of heightened relevance during wartime, when there is a need for healthcare systems to treat complex and infected penetrating and blast-related injuries.

Sections du résumé

Background UNASSIGNED
Antimicrobial resistance is a global health threat resulting in significant morbidity and mortality worldwide. Until recently, in Ukraine, cumulative antibiograms (CuAbgms) have never been available.
Objectives UNASSIGNED
To describe the first CuAbgm developed in Ukraine.
Methods UNASSIGNED
We developed a CuAbgm for the Okhmatdyt National Specialized Children's Hospital using data from WHONET. Antimicrobial susceptibility testing was performed per EUCAST guidelines. The CuAbgm was developed using guidance from CLSI.
Results UNASSIGNED
For
Conclusions UNASSIGNED
In this first-ever CuAbgm developed in Ukraine, high levels of resistance were demonstrated among Gram-negative bacteria. CuAbgms should be prioritized in laboratories in Ukraine to guide empirical antimicrobial therapy, infection control and antimicrobial stewardship policies. This is of heightened relevance during wartime, when there is a need for healthcare systems to treat complex and infected penetrating and blast-related injuries.

Identifiants

pubmed: 39386375
doi: 10.1093/jacamr/dlae156
pii: dlae156
pmc: PMC11462436
doi:

Types de publication

Journal Article

Langues

eng

Pagination

dlae156

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Auteurs

Arkadii Vodianyk (A)

Service Delivery Department, WHO Country Office for Ukraine, Kyiv, Ukraine.

Oksana Holovnia (O)

Department of Bacteriology, National Children's Specialized Hospital Okhmatdyt, Kyiv, Ukraine.

Eugene Diomin (E)

Service Delivery Department, WHO Country Office for Ukraine, Kyiv, Ukraine.

Alyssa R Letourneau (AR)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Mark C Poznansky (MC)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Heal Ukraine Group, Boston, MA, USA.

Erica S Shenoy (ES)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Infection Control, Massachusetts General Hospital and Mass General Brigham, Boston, MA, USA.

Sarah E Turbett (SE)

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

Classifications MeSH